ZBH vs BSX Stock Comparison: AI Score, Valuation, Performance and Upside
Zimmer Biomet and Boston Scientific both operate in medical devices, but Zimmer Biomet concentrates on orthopedic implants for joint reconstruction, while Boston Scientific operates a more diversified portfolio spanning cardiovascular, endoscopy, urology, and neuromodulation categories with a stronger recent growth track record.
Zimmer Biomet offers exposure to steady, demographically-driven orthopedic implant demand, while Boston Scientific offers exposure to a diversified, innovation-driven device portfolio with faster growth in cardiovascular and structural heart categories. Consider whether you prefer Zimmer Biomet's orthopedic stability or Boston Scientific's diversified innovation growth.
BSX holds the edge across 3 of 5 key metrics in this comparison. ZBH leads on both 1-year return (-3.19%) and forward P/E quality (11.13x vs 13.64x for BSX), a relatively favorable combination of momentum and valuation. BSX leads on both revenue growth (7.50%) and operating margin (22.90%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BSX (+33.84%) than for ZBH (+6.60%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to an established leader in knee and hip replacement orthopedic implants
- Believe aging population demographics will continue supporting long-term joint replacement demand
- Value deep surgeon relationships and procedure expertise built over decades
- Are comfortable with growth rates that have historically lagged more innovation-driven device categories
- Want diversified exposure across cardiovascular, endoscopy, urology, and neuromodulation device categories
- Believe continued new product innovation will sustain above-market growth rates
- Value exposure to faster-growing structural heart and electrophysiology segments
- Are comfortable with the research and development investment required to maintain innovation-driven growth
| Metric | ZBH | BSX |
|---|---|---|
| AI scorei | 37.7 | 39.8 |
| AI ranki | #1424 | #1226 |
| Latest closei | $97.35 | $44.32 |
| 1M returni | +10.26% | +4.04% |
| 3M returni | +0.38% | -8.49% |
| 6M returni | +17.76% | -22.04% |
| 1Y returni | -3.19% | -56.00% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ZBH | BSX |
|---|---|---|
| 1Y ago | $9.75K (-2.5%) started 2025-11-03 | $4.5K (-55.0%) started 2025-11-03 |
| 5Y ago | $7.14K (-28.6%) started 2021-11-03 | $10.33K (+3.3%) started 2021-11-03 |
| 10Y ago | $11.21K (+12.1%) started 2016-11-03 | $20.58K (+105.8%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | ZBH | BSX |
|---|---|---|
| Market capi | $19.25B | $67.88B |
| Trailing P/Ei | 24.49 | 18.96 |
| Forward P/Ei | 11.13 | 13.64 |
| Price/Salesi | 2.37 | N/A |
| EV/Revenuei | 3.10 | 3.82 |
| Analyst targeti | $107.57 | $62.69 |
| Target upsidei | +6.60% | +33.84% |
| Metric | ZBH | BSX |
|---|---|---|
| Revenue growthi | 4.80% | 7.50% |
| Earnings growthi | 33.80% | 15.10% |
| EPS growthi | +33.80% | +15.10% |
| FCF margini | +12.82% | +11.68% |
| Operating margini | 17.96% | 22.90% |
| Profit margini | 9.48% | 17.50% |
| ROIC proxyi | 6.41% | 15.34% |
| Return on equityi | 6.41% | 15.34% |
| Dividend yieldi | 0.95% | N/A |
| Payout ratioi | 23.30% | 0.00% |
| Dividend growth streaki | No increase yet | N/A |
| Betai | 0.46 | 0.57 |
| Debt/equityi | 60.17 | 50.15 |
| Current ratioi | 1.69 | 1.24 |
| Quick ratioi | 0.74 | 0.56 |
Over the past year, ZBH and BSX have moved weakly in the same direction (correlation of 0.25), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ZBH | BSX |
|---|---|---|---|
| 1Y | Growthi | -2.53% | -55.05% |
| CAGRi | -2.54% | -55.15% | |
| Volatilityi | 32.78% | 39.12% | |
| Sharpe ratioi | -0.05 | -1.98 | |
| Sortino ratioi | -0.06 | -2.33 | |
| Max drawdowni | 22.87% | 60.39% | |
| Current drawdowni | 5.65% | 57.78% | |
| Avg drawdowni | 11.12% | 38.22% | |
| Ulcer Indexi | 12.10% | 43.16% | |
| Max daily dropi | 15.15% | 17.59% | |
| Max wkly dropi | 14.23% | 19.50% | |
| 5Y | Growthi | -30.63% | +3.29% |
| CAGRi | -7.05% | +0.65% | |
| Volatilityi | 27.18% | 26.80% | |
| Sharpe ratioi | -0.30 | -0.01 | |
| Sortino ratioi | -0.40 | -0.01 | |
| Max drawdowni | 44.52% | 61.55% | |
| Current drawdowni | 32.14% | 59.02% | |
| Avg drawdowni | 23.28% | 11.63% | |
| Ulcer Indexi | 25.28% | 20.82% | |
| Max daily dropi | 15.15% | 17.59% | |
| Max wkly dropi | 14.23% | 19.50% | |
| 10Y | Growthi | +4.60% | +105.76% |
| CAGRi | +0.45% | +7.48% | |
| Volatilityi | 28.47% | 27.85% | |
| Sharpe ratioi | 0.00 | 0.24 | |
| Sortino ratioi | 0.00 | 0.32 | |
| Max drawdowni | 52.63% | 61.55% | |
| Current drawdowni | 42.05% | 59.02% | |
| Avg drawdowni | 22.15% | 9.87% | |
| Ulcer Indexi | 26.85% | 16.69% | |
| Max daily dropi | 15.15% | 17.59% | |
| Max wkly dropi | 27.48% | 19.55% |
| Category | ZBH | BSX |
|---|---|---|
| Company | Zimmer Biomet Holdings, Inc. | Boston Scientific Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A medical device company specializing in orthopedic products including knee and hip replacement implants, along with surgical instruments and related technologies used in joint reconstruction and other orthopedic procedures. | A diversified medical device company developing and manufacturing products across cardiovascular, endoscopy, urology, and neuromodulation categories used in a wide range of minimally invasive medical procedures. |
| Investor focus | Knee and hip replacement procedure volume trends, new product launch adoption, and margin performance amid competitive orthopedic implant pricing dynamics. | Cardiovascular and structural heart product growth, new product launch pipeline execution, and overall revenue growth trajectory across diversified device categories. |
- Established leadership position in knee and hip replacement implants provides deep surgeon relationships and procedure expertise
- Broad orthopedic product portfolio spans joint reconstruction, sports medicine, and other related surgical categories
- Aging population demographics support long-term underlying demand growth for joint replacement procedures
- Diversified product portfolio spans cardiovascular, endoscopy, urology, and neuromodulation, reducing reliance on any single device category
- Strong track record of new product innovation and launches has driven above-market growth rates in recent periods
- Structural heart and electrophysiology categories provide exposure to some of the faster-growing segments within medical devices
- Orthopedic implant pricing faces ongoing competitive pressure within group purchasing and hospital procurement negotiations
- Procedure volumes can be affected by hospital staffing constraints and broader healthcare utilization patterns
- Growth rates have historically lagged more innovation-driven medical device categories like cardiovascular devices
- Product recalls or safety issues in any given device category could affect both revenue and reputation
- Innovation-driven growth strategy requires sustained research and development investment to maintain new product pipeline
- Competitive medical device landscape includes numerous other large diversified and specialized device makers
Compare more than two at a time
This page is a fixed writeup on ZBH and BSX. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ZBH and BSX, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.